Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy

1 Jan 2021

Abstract excerpt

Immune checkpoint blockade elicits durable anti-cancer responses in the clinic, however a large proportion of patients do not benefit from treatment. Several mechanisms of innate and acquired resistance to checkpoint blockade have been defined and include mutations of MHC I and IFNγ signaling pathways. However, such mutations occur in a low frequency of patients and additional mechanisms have yet to be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Immunotherapy and Biomarkers
Share to Immune cells in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33796402
DOI: 10.1080/2162402x.2021.1881268

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapyPMID 33796402Read ↗

Inhibition of CDK4/6 Overcomes Primary Resistance to PD-1 Blockade in Malignant MesotheliomaSemantic proximity Read ↗

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibitionSemantic proximity Read ↗

Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cellsSemantic proximity Read ↗

Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.Semantic proximity Read ↗

In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 TherapiesSemantic proximity Read ↗

Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell ResistanceSemantic proximity Read ↗

Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer respondersSemantic proximity Read ↗

CREB5 promotes immunotherapy resistance via tumor-intrinsic collagen matrix depositionSemantic proximity Read ↗

Clonal tracing reveals diverse patterns of response to immune checkpoint blockadeSemantic proximity Read ↗

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.Semantic proximity Read ↗

Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.Semantic proximity Read ↗

Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine triple-negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.